NovoCure
NVCR
272 hedge funds and large institutions have $4.74B invested in NovoCure in 2020 Q1 according to their latest regulatory filings, with 51 funds opening new positions, 102 increasing their positions, 83 reducing their positions, and 39 closing their positions.
31% more first-time investments, than exits
New positions opened: 51 | Existing positions closed: 39
23% more repeat investments, than reductions
Existing positions increased: 102 | Existing positions reduced: 83
4% more funds holding
Funds holding: 262 → 272 (+10)
0.6% more ownership
Funds ownership: 70.14% → 70.74% (+0.6%)
0% more funds holding in top 10
Funds holding in top 10: 6 → 6 (0)
19% less capital invested
Capital invested by funds: $5.83B → $4.74B (-$1.09B)
21% less call options, than puts
Call options by funds: $80.5M | Put options by funds: $102M
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Capital International Investors
Los Angeles,
California
|
+$92.9M |
| 2 |
CS
Credit Suisse
Zurich,
Switzerland
|
+$25.6M |
| 3 |
Macquarie Group
Sydney, NSW 2000,
Australia
|
+$25.4M |
| 4 |
RCM
RA Capital Management
Boston,
Massachusetts
|
+$20.5M |
| 5 |
Wells Fargo
San Francisco,
California
|
+$16.4M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Fidelity Investments
Boston,
Massachusetts
|
-$26.9M |
| 2 |
Baillie Gifford & Co
Edinburgh,
United Kingdom
|
-$21.5M |
| 3 |
Invesco
Atlanta,
Georgia
|
-$21.4M |
| 4 |
Two Sigma Advisers
New York
|
-$21.3M |
| 5 |
GIP
Granite Investment Partners
El Segundo,
California
|
-$18.3M |
NVCR Hedge Fund Activity: Q1 2020 in Review
272 of the 4,547 institutional investors tracked by Wall St. Rank reported a position in NovoCure (NVCR) for Q1 2020, worth a combined $4.74B — down 19% from $5.83B a quarter earlier.
Buyers outnumbered sellers: 51 funds opened new NVCR positions and 39 closed out — a net gain of 12 holders — while 102 added to existing stakes and 83 trimmed.
The largest buyer was Capital International Investors, adding an estimated $92.9M. The largest seller was Fidelity Investments, cutting an estimated $26.9M.
- 272 institutional investors held NovoCure (NVCR) as of Q1 2020, up from 262 in Q4 2019.
- Funds reported $4.74B of NovoCure stock for Q1 2020, down 19% quarter-over-quarter.
- 51 funds opened new NovoCure positions in Q1 2020 and 39 closed out, a net change of +12 holders.
- The largest NovoCure buyer in Q1 2020 was Capital International Investors, an estimated $92.9M added.
- The largest NovoCure seller in Q1 2020 was Fidelity Investments, an estimated $26.9M sold.
Based on aggregated 13F filings for Q1 2020.